Alaunos Therapeutics, Inc.
corporate_fare Company Profile
Alaunos Therapeutics, Inc. (NASDAQ:TCRT) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 27 items for TCRT at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-16, rated 8/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 8 rated 8 or above. Recent SEC coverage for TCRT spans 10-Q, PRE 14A, S-3, 8-K.
Recent high-impact activity:
- Alaunos 10-Q: $350M PIPE Erases Going-Concern Doubt, But 381M Conversion Shares Loom
- Alaunos Proxy Seeks Approval to Convert Preferred Into 381.4M Shares and Lift Authorized Stock to 400M
- Alaunos Registers 382.1M Shares for Resale From Velaris Merger and $350M PIPE
- Nasdaq Closes Delisting Matter as Alaunos Regains $2.5M Equity Compliance
- Alaunos Says $350M Velaris Financing Restores Nasdaq Equity Compliance
Financial Snapshot
Short Interest & Short Volume
1.00 days to coverFINRA reported short interest of 184,372 shares in TCRT as of the October 30, 2026 settlement, a 77.5% decrease from the prior period — about 1.0 days to cover at its recent average daily volume. On November 20, 2026, 24.9% of TCRT volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Low riskFiling-implied dilution signals for TCRT, detected from its recent SEC filings · based on capital-structure filings through 2026-09-21.
Registered Direct Offering Priced · Best-Efforts Structure
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →